Clinical trials: HIV Coinfection
HIV-1-infection, COVID-19
HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV
HIV CoCo is a European multi-centre, multi-country, retrospective, observational case-control study that will aim to describe clinical outcomes and identify risk factors for People Living With HIV (PLWHIV) who are co-infected…
- Trial name
- HIV CoCo (NCT05481216)
- Testing
- COVID-19, HIV-1 infection
- Where
- 23 sites in Belgium, France and 3 more
- Volunteers
- 2,598 people
- Sponsor
- NEAT ID Foundation
HIV Infections, Hepatitis C
The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin
This study will evaluate how controlling HIV infection with HAART (highly active antiretroviral therapy) affects the response to hepatitis C treatment with peginterferon alpha-2b and ribavirin in HIV-infected patients with…
- Trial name
- NCT00031343
- Testing
- highly active antiretroviral therapy (HAART)
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A study of the efficacy and safety of the combination of daclatasvir and sofosbuvir in the treatment of hepatitis C virus and HIV coinfection.
- Trial name
- NCT02032888
- Testing
- Daclatasvir, Sofosbuvir
- Where
- 37 sites in United States
- Volunteers
- 238 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections, Tuberculosis
Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in Patients With TB/HIV Co-infection in South Africa
The overall aim of the project is to evaluate rifabutin (RBT) as a replacement for rifampicin (RMP), for the combined treatment of tuberculosis and HIV infection.
- Trial name
- NCT00640887
- Testing
- rifabutin in combination with efavirenz, rifabutin in combination with nevirapine, rifabutin in combination with lopinavir/ritonavir
- Where
- South Africa
- Volunteers
- 48 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV, Hepatitis C
Safety Study of Raltegravir in HIV/HCV Co-infected Patients
Current European AIDS Clinical Society (EACS) guidelines for the treatment of HIV infection recommend a combination antiretroviral regimen composed of two nucleoside reverse transcriptase inhibitors plus a ritonavir boosted…
- Trial name
- NCT01225705
- Testing
- raltegravir, Atazanavir/ritonavir
- Where
- 8 sites in Germany
- Sponsor
- University Hospital, Bonn
Hepatitis C, Hiv
Integrating HIV and Hepatitis C Screening in an Urban Emergency Department
This randomized controlled trial was implemented to evaluate the effect of integrating rapid Hepatitis C (HCV) testing into a pre-existing screening program for Human Immunodeficiency Virus (HIV) on HIV test acceptance and…
- Conditions
- Hepatitis C, Hiv, HIV/AIDS, HCV Coinfection
- Trial name
- NCT03252483
- Testing
- Bundled HCV/HIV Screening, HIV Screening
- Where
- United States
- Volunteers
- 478 people, healthy volunteers welcome
- Sponsor
- New York City Health and Hospitals Corporation
HIV
HIV Infection and Risk Related Coinfections/Comorbidities in Indonesia
INA-PROACTIVE is a multicenter, prospective, observational cohort study of HIV positive antiretroviral-naïve and treatment-experienced individuals. No investigational treatment or intervention will be used by this study.
- Trial name
- INAPROACTIVE (NCT03663920)
- Where
- 19 sites in Indonesia
- Volunteers
- 4,336 people
- Sponsor
- Ina-Respond
HIV
HIV-DNA Dynamics in HIV Monoinfected or HIV/HCV Coinfected Patients
New markers of viral activity are now under investigation. Aim of the study is to investigate the efficacy of new antiretroviral drugs by monitoring HIV-DNA dynamics in HIV-positive population.
- Trial name
- ViDyMoCo (NCT02836782)
- Testing
- Blood sample withdrawal
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Catholic University of the Sacred Heart
Monkeypox, HIV Coinfection
Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV
This data collection study aims to describe and compare the outcomes of Mpox on people living with HIV (PLHIV) and HIV-negative individuals who are on pre-exposure prophylaxis (PrEP).
- Trial name
- MASH1 (NCT05965427)
- Testing
- No intervention
- Where
- 9 sites in France, Poland and 2 more
- Volunteers
- 2,000 people
- Sponsor
- NEAT ID Foundation
HIV, Hepatitis C
Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy
This study will evaluate the impact of standard hepatitis C virus treatment on brain deficits in people who are infected with both HIV and the hepatitis C virus.
- Conditions
- HIV, Hepatitis C, Infections
- Trial name
- NCT00747539
- Testing
- Pegylated interferon alfa and ribavirin (PEG-IFN/RBV)
- Where
- 4 sites in United States
- Volunteers
- 330 people
- Sponsor
- University of California, Los Angeles
Liver Fibrosis, Hepatitis C
Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis
The primary objective of this study is to assess the safety and tolerability of simtuzumab (formerly GS-6624) in HIV and/or hepatitis C virus (HCV)-infected adults with evidence of liver fibrosis.
- Conditions
- Liver Fibrosis, Hepatitis C, HIV, HIV/HCV Co-infection
- Trial name
- NCT01707472
- Testing
- Simtuzumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Gilead Sciences
Hepatitis B, Human Immunodeficiency Virus
Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients
Confirm the safety of maraviroc when used as a component of combination antiretroviral therapy in HIV and Hepatitis co-infected patients.
- Conditions
- Hepatitis B, Human Immunodeficiency Virus, Hepatitis C, Chronic
- Trial name
- NCT00782301
- Testing
- maraviroc, etravirine
- Where
- 18 sites in United States, Canada and 1 more
- Sponsor
- ViiV Healthcare
Depression, HIV Infections
Trial of Citalopram for the Prevention of Depression
With the improved prognosis of human immunodeficiency virus (HIV) infection, end stage liver disease due to hepatitis C (HCV) now represents a major cause of morbidity and mortality in people with HIV.
- Conditions
- Depression, HIV Infections, Hepatitis C
- Trial name
- PICCO (NCT00317746)
- Testing
- Citalopram
- Where
- Canada
- Volunteers
- 76 people
- Sponsor
- Marina Klein
HIV Infections, Hepatitis B Virus
A Surveillance Program for the Detection of Hepatitis B Virus (HBV) Resistance to Tenofovir in HIV-HBV co-Infected Patients
Human immunodeficiency virus/Hepatitis B virus (HIV/HBV) co-infections are frequently observed due to shared routes of transmission, with reported figures indicating 6-9% of HIV-infected individuals in developed countries are…
- Trial name
- NCT00660361
- Where
- Australia
- Volunteers
- 92 people
- Sponsor
- Bayside Health
HIV-hepatitis Co-infection, HIV Infections
Innate Immunity in HIV Positive Patients Co-infected With Hepatitis C Virus (HCV) or Hepatitis B Virus (HBV)
Data from this study will provide the first information how the innate immune system may be altered in HIV-HCV and HIV-HBV co-infected individuals, and describe Toll-like receptor changes with HIV co-infection therapy.
- Trial name
- NCT00662194
- Where
- Australia
- Volunteers
- 40 people
- Sponsor
- Bayside Health
HIV
HIV-Tb Confections Among HIV Patients
A cross sectional study would be done for prevalence of HIV-Tb. co infection among patients of HIV enrolled at ART centre, Khagaria, India, during June' 2015 to May' 2016.
- Trial name
- NCT02964767
- Where
- India
- Volunteers
- 219 people
- Sponsor
- Singh, Ranjan Kumar, M.D.
HIV Infections
Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin β in Patients Coinfected HCV/HIV
The purpose of this study is to compare the early virological response (EVR = undetectable [ribonucleic acid-hepatitis C virus] RNA-HCV or a reduction of > 2 log10) of patients with chronic hepatitis C coinfected with HIV treated…
- Trial name
- NCT00356486
- Testing
- Peginterferon alfa-2a, Ribavirin, epoetin-β, Peginterferon alfa-2a + Ribavirin for 12 weeks
- Where
- 12 sites in Spain
- Volunteers
- 74 people
- Sponsor
- Germans Trias i Pujol Hospital
Human Immunodeficiency Virus (HIV) Infection
Same-day Versus Rapid ART Initiation in HIV-positive Individuals Presenting With Symptoms of Tuberculosis
SaDAPT is a pragmatic, randomized, therapeutic-use trial comparing two approaches ("ART first" versus "TB results first") for the timing of ART initiation in PLHIV with presumptive TB, but no signs of central nervous system (CNS)…
- Trial name
- SaDAPT (NCT05452616)
- Testing
- ART first- Therapeutic use trial, TB results first- Therapeutic use trial
- Where
- 2 sites in Lesotho, Malawi
- Volunteers
- 610 people
- Sponsor
- University Hospital, Basel, Switzerland
HIV-1 and HSV-2 Coinfection, HIV Infections
Usage of Acyclovir for Suppression of HIV-1 and HSV-2 Coinfected Persons in Cameroon
The study proposed that both clinical and subclinical HSV reactivation is associated with increased HIV shedding from mucosal surfaces, which may increase the infectiousness of HIV-1/HSV-2 coinfected persons.
- Trial name
- NCT00209313
- Testing
- Acyclovir
- Where
- Cameroon
- Volunteers
- 40 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Hepatitis C
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
The purpose of this study is to evaluate the effectiveness and safety of telaprevir, given with pegylated-interferon-alfa-2a (Peg-IFN-alfa-2a) and ribavirin (RBV) in the treatment of hepatitis C in patients infected with both…
- Trial name
- INSIGHT (NCT01513941)
- Testing
- Telaprevir, Ribavirin, Pegylated-Interferon-alfa-2a
- Where
- 31 sites in Australia, Brazil and 6 more
- Volunteers
- 163 people
- Sponsor
- Janssen-Cilag International NV